Cost-effectiveness of Levosimendan in Patients With Acute Heart Failure
Authors:
- Francesco FedeleFFFrancesco Fedele
- Alessandra DʼambrosiADAlessandra Dʼambrosi
- Noemi BrunoNBNoemi Bruno
- Carmen CairaCCCarmen Caira
- Bruno BrasolinBBBruno Brasolin
- Massimo ManconeMMMassimo Mancone
- 1 October 2011
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 58 (4) , 363-366
Abstract
Heart failure is a major public health problem because of its high prevalence and impact on mortality, morbidity, quality of life, and social costs. The aim of this analysis was to estimate the effects of the novel inodilator levosimendan versus standard inotropic therapy (ST) of dobutamine in acute heart failure. A study population of 292 patients with acute heart failure was derived from an observational registry of patients referred to our department. Of these, 147 patients received iv levosimendan (0.05–0.1 μg·kg−1·min−1 for 24 hours), and 145 patients were treated with ST. Duration of hospitalization, survival at 1 month, and the rehospitalization rate during the year after the index hospitalization were evaluated. Cost-effectiveness analysis was performed. The mean length of hospitalization was 12.08 and 13.57 days in the levosimendan and ST groups, respectively (P < 0.05). Rehospitalization rates were lower in the levosimendan group at 6 months (1.44% vs. 2.3%; P < 0.05) and 12 months (7.6% vs. 14.3%; P < 0.05). Mortality rate at 1 month was 2.1% versus 6.9% in the levosimendan and ST groups, respectively (P < 0.05). The per-capita cost of treatment with levosimendan was €78.86 higher than that with ST during the first hospitalization but €280.22 lower when the rehospitalization rate was considered.Keywords
This publication has 13 references indexed in Scilit:
- Levosimendan for the treatment of acute severe heart failure: A meta-analysis of randomised controlled trialsInternational Journal of Cardiology, 2010
- Trends in hospitalization for heart failure in Italy 2001–2003Journal of Cardiovascular Medicine, 2009
- Effects of Levosimendan on the Energy Balance: Preclinical and Clinical EvidenceJournal of Cardiovascular Pharmacology, 2009
- The costs of treating acute heart failure: an economic analysis of the SURVIVE trialJournal of Medical Economics, 2008
- Nationwide survey on acute heart failure in cardiology ward services in ItalyEuropean Heart Journal, 2005
- Análise de custos do tratamento de episódios de descompensação aguda de insuficiência cardíaca: levosimendan versus dobutaminaArquivos Brasileiros de Cardiologia, 2005
- Acute heart failure syndromes: the ‘Cinderella’ of heart failure researchEuropean Heart Journal Supplements, 2005
- Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of CardiologyEuropean Heart Journal, 2005
- Intravenous Levosimendan Treatment is Cost-Effective Compared with Dobutamine in Severe Low-Output Heart Failure: An Analysis Based on the International LIDO TrialEuropean Journal of Heart Failure, 2003
- Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trialThe Lancet, 2002